A Phase 1b, Randomized, Open-Label Trial to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB097 in Combination with Pembrolizumab in Melanoma Patients with Primary Resistance to an Anti-PD-1-Containing Immunotherapy (MELODY-1)

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507377-17-00

Acronym

MB097-01

Enrollment

Registered

2024-07-22

Start date

2024-08-28

Completion date

Unknown

Last updated

2025-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Melanoma

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Italy, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026